Abstract:Background: Cardiac hypertrophy is an important prepathology of, and will ultimately lead to, heart failure. However, the mechanisms underlying pathological cardiac hypertrophy remain largely unknown. This study aims to elucidate the effects and mechanisms of HINT1 (histidine triad nucleotide-binding protein 1) in cardiac hypertrophy and heart failure. Methods: HINT1 was downregulated in human hypertrophic heart samples compared with nonhypertrophic samples by mass spectrometry analysis. Hint1 knockout mice were challenged with transverse aortic constriction surgery. Cardiac-specific overexpression of HINT1 mice by intravenous injection of adeno-associated virus 9 (AAV9)-encoding Hint1 under the cTnT (cardiac troponin T) promoter were subjected to transverse aortic construction. Unbiased transcriptional analyses were used to identify the downstream targets of HINT1. AAV9 bearing shRNA against Hoxa5 (homeobox A5) was administrated to investigate whether the effects of HINT1 on cardiac hypertrophy were HOXA5-dependent. RNA sequencing analysis was performed to recapitulate possible changes in transcriptome profile.Coimmunoprecipitation assays and cellular fractionation analyses were conducted to examine the mechanism by which HINT1 regulates the expression of HOXA5. Results: The reduction of HINT1 expression was observed in the hearts of hypertrophic patients and pressure overloaded-induced hypertrophic mice, respectively. In Hint1-deficient mice, cardiac hypertrophy deteriorated after transverse aortic construction. Conversely, cardiac-specific overexpression of HINT1 alleviated cardiac hypertrophy and dysfunction. Unbiased profiler polymerase chain reaction array showed HOXA5 is 1 target for HINT1, and the cardioprotective role of HINT1 was abolished by HOXA5 knockdown in vivo. Hoxa5 was identified to affect hypertrophy through the TGF-beta (transforming growth factor beta) signal pathway. Mechanically, HINT1 inhibited PKC beta 1 (protein kinase C beta type 1) membrane translocation and phosphorylation via direct interaction, attenuating the MEK/ERK/YY1 (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/yin yang 1) signal pathway, downregulating HOXA5 expression, and eventually attenuating cardiac hypertrophy. Conclusions: HINT1 protects against cardiac hypertrophy through suppressing HOXA5 expression. These findings indicate that HINT1 may be a potential target for therapeutic interventions in cardiac hypertrophy and heart failure.

FKBP12.6 Protects Heart from AngII-induced Hypertrophy Through Inhibiting Ca2+ /Calmodulin-Mediated Signalling Pathways in Vivo and in Vitro.

Transgenic analysis of the role of FKBP12.6 in cardiac function and intracellular calcium release

Oestrogen Protects FKBP12.6 Null Mice from Cardiac Hypertrophy.

Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy.

Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload.

FKBP12 is a critical regulator of the heart rhythm and the cardiac voltage-gated sodium current in mice

Hint1 (Histidine Triad Nucleotide-Binding Protein 1) Attenuates Cardiac Hypertrophy Via Suppressing Hoxa5 (Homeobox A5) Expression

Deletion of protein kinase B2 preserves cardiac function by blocking interleukin-6-mediated injury and restores blood pressure during angiotensin II/high-salt-diet-induced hypertension

Sirtuin 6 Protects Cardiomyocytes from Hypertrophy in Vitro Via Inhibition of NF‐κB‐dependent Transcriptional Activity

Fibulin-2 Deficiency Attenuates Angiotensin Ii-Induced Cardiac Hypertrophy By Reducing Transforming Growth Factor-Beta Signalling

Interleukin-6 Deficiency Attenuates Angiotensin II-induced Cardiac Pathogenesis with Increased Myocyte Hypertrophy.

Dickkopf-3 attenuates pressure overload-induced cardiac remodelling.

DKK3 Overexpression Attenuates Cardiac Hypertrophy and Fibrosis in an Angiotensin-Perfused Animal Model by Regulating the ADAM17/ACE2 and GSK-3β/β-catenin Pathways

PFKP inhibition protects against pathological cardiac hypertrophy by regulating protein synthesis

Cd38 Promotes Angiotensin Ii-Induced Cardiac Hypertrophy

Up-regulation of P27kip1 Contributes to Nrf2-mediated Protection Against Angiotensin II-induced Cardiac Hypertrophy

The RING-domain E3 ubiquitin ligase RNF146 promotes cardiac hypertrophy by suppressing the LKB1/AMPK signaling pathway

LTBP2 Knockdown Ameliorates Cardiac Fibrosis and Apoptosis via Attenuating NF‐κB Signaling Pathway and Oxidative Stress in Mice with Cardiac Hypertrophy

A Disintegrin and Metalloprotease-22 Attenuates Hypertrophic Remodeling in Mice Through Inhibition of the Protein Kinase B Signaling Pathway.

Cardiac-specific BACH1 Ablation Attenuates Pathological Cardiac Hypertrophy by Inhibiting the Ang II Type 1 Receptor Expression and the Ca2+/CaMKII Pathway.

FKBP12.6-knockout mice display hyperinsulinemia and resistance to high-fat diet-induced hyperglycemia.